Abivax shares jump 25% on obefazimod safety data
Get the Tech newsletter
Daily tech — startups, AI labs, chips, the launches that shape the next decade. Free.
- Abivax disclosed additional safety data for its experimental ulcerative colitis drug obefazimod on Monday night, seemingly allaying at least some of the safety concerns that had flared in recent weeks
- Abivax's U.S.-listed shares climbed roughly 25% overnight into Tuesday morning in response to the new data
- Earlier this month, obefazimod delivered strong efficacy in a closely watched maintenance trial, with far more participants on the study drug entering a period of no symptoms versus those on placebo
- A number of cancer cases among people taking obefazimod in those trials had previously raised safety questions, sending the company's shares plummeting
- The drug remains experimental, and the new disclosure is framed as reassurance rather than a complete resolution of the safety debate
Why it matters: Obefazimod is Abivax's lead asset, and the earlier cancer-signal scare had put its regulatory path at risk; a 25% overnight rebound shows investors now believe the latest safety update has bought the drug meaningful breathing room, though the source notes only "some" concerns were eased — leaving the broader cancer question unresolved for regulators and prescribers.
